ZM C001
Alternative Names: ZM-C001Latest Information Update: 06 Jan 2023
At a glance
- Originator Medicinal Bioconvergence Research Center
- Class Hepatoprotectants; Small molecules
- Mechanism of Action Lysine tRNA ligase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-alcoholic steatohepatitis
Most Recent Events
- 12 Dec 2022 Preclinical trials in Non-alcoholic steatohepatitis in South Korea (unspecified route) before December 2022 (Zymedi pipeline, December 2022)
- 12 Dec 2022 Pharmacodynamics and adverse events data from preclinical studies in Non-alcoholic steatohepatitis released by Zymedi (Zymedi pipeline, December 2022)